WALTHAM, Mass., Sept. 20, 2017 /PRNewswire/ -- Syndax
Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage
biopharmaceutical company developing entinostat and SNDX-6352 in
multiple cancer indications, today announced an update to the time
of the Company's presentation at the Cantor Fitzgerald Global
Healthcare Conference. Briggs W.
Morrison, M.D., Chief Executive Officer of Syndax, will now
present on September 25, 2017 at
11:30 am EDT at the InterContinental
New York Barclay Hotel.
A live webcast of the Company's presentation can be accessed
from the Investor section of the Company's website
at www.syndax.com, where a replay of the event will also be
available for a limited time.
About Syndax Pharmaceuticals, Inc.
Syndax is a clinical stage biopharmaceutical company developing
an innovative pipeline of cancer therapies. Our lead product
candidate, entinostat, which was granted Breakthrough Therapy
designation by the FDA following positive results from our Phase 2b
clinical trial, ENCORE 301, is currently being evaluated in a Phase
3 clinical trial for advanced hormone receptor positive, human
epidermal growth factor receptor 2 negative breast cancer. Given
its potential ability to block the function of immune suppressive
cells in the tumor microenvironment, entinostat is also being
evaluated in combination with approved PD-1 antagonists. Ongoing
Phase 1b/2 clinical trials combine entinostat with KEYTRUDA from
Merck & Co., Inc. for non-small cell lung cancer, melanoma and
colorectal cancer; with TECENTRIQ® from Genentech, Inc.
for triple negative breast cancer; and with BAVENCIO®
from Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer. Our second
product candidate, SNDX-6352, is a monoclonal antibody that blocks
the CSF-1 receptor and may also block the function of immune
suppressive cells in the tumor microenvironment. SNDX-6352 is being
evaluated in Phase 1 clinical trials and is expected to be
developed to treat a variety of cancers.
Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902
Media Contact
Eliza Schleifstein
Argot Partners
eliza@argotpartners.com
Tel 973.361.1546
SNDX-G
View original
content:http://www.prnewswire.com/news-releases/syndax-pharmaceuticals-announces-updated-presentation-time-at-the-cantor-fitzgerald-global-healthcare-conference-300522489.html
SOURCE Syndax Pharmaceuticals